ArticleOphthalmology2012
Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma.
Article in Ophthalmology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 236 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
236 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.ESMO open · 2026Guideline
- [Liquid biopsy proteomics in ophthalmology : A clinical and scientific perspective].Die Ophthalmologie · 2026Pooled it
- Management of Uveal Melanoma: Updated Cancer Care Alberta Clinical Practice Guideline.Current oncology (Toronto, Ont.) · 2023Guideline
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.Journal for immunotherapy of cancer · 2023Guideline
- PRAME predicting outcome in uveal melanoma.The journal of pathology. Clinical research · 2026Article
- Functional validation of driver mutation-specific uveal melanoma biomarkers: role of COL9A3 in cancer cell plasticity.The Journal of pathology · 2026Article
- Deep Learning and Experimental Validation of BRCA1-Associated Protein-1 Missense Variant Pathogenicity in Uveal Melanoma.Ophthalmology science · 2026Article
- Identification and Validation of an E2F Targets-Related Gene Signature Risk Score Predicting the Prognosis of Patients with Uveal Melanoma.Ocular oncology and pathology · 2026Article
- Review
- Article
- Article
- Modeled Aqueous Humor Protein Concentrations to Enable Biomarker Development in Uveal Melanoma.International journal of molecular sciences · 2026Article
- Ephrin Receptors and Ephrin Ligands in Uveal Melanoma: A Big Data Analysis Using Web Resources.International journal of molecular sciences · 2025Article
- Article
- A prognostic model for uveal melanoma in Asian populations: a comparative analysis of clinical features and gene expression patterns using the TRACE and TCGA data.BMC ophthalmology · 2025Article
- Clinical utility of pembrolizumab in the management of orbital recurrence of uveal melanoma: case report.American journal of ophthalmology case reports · 2025Article
- Characterization of Early Metastatic Subpopulations in Uveal Melanoma: Single-Cell Insights Into SPP1+ Cells and Their Interactions With Macrophages.Investigative ophthalmology & visual science · 2025Article
- Identification of two distinct uveal melanoma subtypes based on the immune cell infiltration of the primary tumour.Cancer immunology, immunotherapy : CII · 2025Article
- The Small Choroidal Melanoma: Diagnosis, Treatment Outcomes, and Unending Controversy.Seminars in ophthalmology · 2025Review
- Article
176 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
21 authors.
Funding
Abstract
purposeThis study evaluates the prognostic performance of a 15 gene expression profiling (GEP) assay that assigns primary posterior uveal melanomas to prognostic subgroups: class 1 (low metastatic risk) and class 2 (high metastatic risk).
designProspective, multicenter study.
participantsA total of 459 patients with posterior uveal melanoma were enrolled from 12 independent centers. TESTING: Tumors were classified by GEP as class 1 or class 2. The first 260 samples were also analyzed for chromosome 3 status using a single nucleotide polymorphism assay. Net reclassification improvement analysis was performed to compare the prognostic accuracy of GEP with the 7th edition clinical Tumor-Node-Metastasis (TNM) classification and chromosome 3 status.
main outcome measuresPatients were managed for their primary tumor and monitored for metastasis.
resultsThe GEP assay successfully classified 446 of 459 cases (97.2%). The GEP was class 1 in 276 cases (61.9%) and class 2 in 170 cases (38.1%). Median follow-up was 17.4 months (mean, 18.0 months). Metastasis was detected in 3 class 1 cases (1.1%) and 44 class 2 cases (25.9%) (log-rank test, P<10(-14)). Although there was an association between GEP class 2 and monosomy 3 (Fisher exact test, P<0.0001), 54 of 260 tumors (20.8%) were discordant for GEP and chromosome 3 status, among which GEP demonstrated superior prognostic accuracy (log-rank test, P = 0.0001). By using multivariate Cox modeling, GEP class had a stronger independent association with metastasis than any other prognostic factor (P<0.0001). Chromosome 3 status did not contribute additional prognostic information that was independent of GEP (P = 0.2). At 3 years follow-up, the net reclassification improvement of GEP over TNM classification was 0.43 (P = 0.001) and 0.38 (P = 0.004) over chromosome 3 status.
conclusionsThe GEP assay had a high technical success rate and was the most accurate prognostic marker among all of the factors analyzed. The GEP provided a highly significant improvement in prognostic accuracy over clinical TNM classification and chromosome 3 status. Chromosome 3 status did not provide prognostic information that was independent of GEP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.